Доступ предоставлен для: Guest
Портал Begell Электронная Бибилиотека e-Книги Журналы Справочники и Сборники статей Коллекции
Critical Reviews™ in Immunology
Импакт фактор: 1.404 5-летний Импакт фактор: 3.347 SJR: 0.706 SNIP: 0.55 CiteScore™: 2.19

ISSN Печать: 1040-8401
ISSN Онлайн: 2162-6472

Выпуски:
Том 40, 2020 Том 39, 2019 Том 38, 2018 Том 37, 2017 Том 36, 2016 Том 35, 2015 Том 34, 2014 Том 33, 2013 Том 32, 2012 Том 31, 2011 Том 30, 2010 Том 29, 2009 Том 28, 2008 Том 27, 2007 Том 26, 2006 Том 25, 2005 Том 24, 2004 Том 23, 2003 Том 22, 2002 Том 21, 2001 Том 20, 2000 Том 19, 1999 Том 18, 1998 Том 17, 1997 Том 16, 1996 Том 15, 1995 Том 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.2015012558
pages 49-57

Interleukin 35−Producing B Cells (i35-Breg): A New Mediator of Regulatory B-Cell Functions in CNS Autoimmune Diseases

Charles E. Egwuagu
Molecular Immunology Section, Laboratory of Immunology, National Eye Institute (NEI), National Institutes of Health (NIH), Bethesda, Maryland 20892
Cheng-Rong Yu
Molecular Immunology Section, Laboratory of Immunology, National Eye Institute (NEI), National Institutes of Health (NIH), Bethesda, Maryland 20892

Краткое описание

Neuroinflammation contributes to neuronal deficits in neurodegenerative CNS (central nervous system) autoimmune diseases, such as multiple sclerosis and uveitis. The major goal of most treatment modalities for CNS autoimmune diseases is to limit inflammatory responses in the CNS; immune-suppressive drugs are the therapy of choice. However, lifelong immunosuppression increases the occurrence of infections, nephrotoxicity, malignancies, cataractogenesis, and glaucoma, which can greatly impair quality of life for the patient. Biologics that target pathogenic T cells is an alternative approach that is gaining wide acceptance as indicated by the popularity of a variety of Food and Drug Administration (FDA)-approved anti-inflammatory compounds and humanized antibodies such as Zenapax, Etanercept, Remicade, anti-ICAM, rapamycin, or tacrolimus. B cells are also potential therapeutic targets because they provide costimulatory signals that activate pathogenic T cells and secrete cytokines that promote autoimmune pathology. B cells also produce autoreactive antibodies implicated in several organ-specific and systemic autoimmune diseases including lupus erythematosus, Graves' disease, and Hashimoto's thyroiditis. On the other hand, recent studies have led to the discovery of several regulatory B-cell (Breg) populations that suppress immune responses and autoimmune diseases. In this review, we present a brief overview of Breg phenotypes and in particular, the newly discovered IL35-producing regulatory B cell (i35-Breg). We discuss the critical roles played by i35-Bregs in regulating autoimmune diseases and the potential use of adoptive Breg therapy in CNS autoimmune diseases.


Articles with similar content:

Regulation Generation: The Suppressive Functions of Human Regulatory T Cells
Critical Reviews™ in Immunology, Vol.32, 2012, issue 1
Kevin D. Cooper, Thomas S. McCormick, Wendy A. Goodman
The Role of Bruton's Tyrosine Kinase in Immune Cell Signaling and Systemic Autoimmunity
Critical Reviews™ in Immunology, Vol.38, 2018, issue 1
Esmee K. Van Der Ploeg, Rudi W. Hendriks, Jasper Rip, Odilia B. J. Corneth
Regulatory T-cell Trafficking: From Thymic Development to Tumor-Induced Immune Suppression
Critical Reviews™ in Immunology, Vol.30, 2010, issue 5
Adam Mailloux, M. Rita I. Young
A CCL2-Based Fusokine as a Novel Biopharmaceutical for the Treatment of CCR2-Driven Autoimmune Diseases
Critical Reviews™ in Immunology, Vol.30, 2010, issue 5
Jacques Galipeau, Moutih Rafei
Opportunities for Translation from the Bench: Therapeutic Intervention of the JAK/STAT Pathway in Neuroinflammatory Diseases
Critical Reviews™ in Immunology, Vol.35, 2015, issue 6
Yudong Liu, Etty N. Benveniste, Hongwei Qin, Sara A. Gibson